SCHEMBL5018181

SCHEMBL5018181

NCCN(CCN)C(=O)C[C@H](N)C(=O)N[C@@H](CCc1ccccc1)C(=O)Nc1cc(Cl)nc(Cl)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CALCRL Q16602 1/20 0.39
CHRNB2 P17787 1/20 0.38
CHRNB4 P30926 1/20 0.38
CHRNA3 P32297 1/20 0.38
CHRNA4 P43681 1/20 0.38
MMP3 P08254 6/20 0.36
MMP1 P03956 3/20 0.36
MMP2 P08253 3/20 0.36
MMP12 P39900 2/20 0.36
MMP13 P45452 2/20 0.36
ERAP2 Q6P179 3/20 0.35
ERAP1 Q9NZ08 3/20 0.35
LNPEP Q9UIQ6 2/20 0.35
CTSC P53634 1/20 0.35
MMP9 P14780 2/20 0.35
ROCK1 Q13464 1/20 0.35
IL1RN P18510 1/20 0.35
S1PR1 P21453 1/20 0.35
BCHE P06276 2/20 0.35
ACHE P22303 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5018461 0.91 CHRNB2 (0.37) CALCRLCHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL5018378 0.89 CALCRL (0.39) CALCRLCHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL5018305 0.87 FPR2 (0.44) CALCRLMMP2
SCHEMBL5018143 0.87 MMP2 (0.44) CALCRLCHRNB2CHRNB4CHRNA3CHRNA4
Hydrochloric Acid SCHEMBL2748013 0.86 MMP2 (0.44) CALCRLCHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL5019418 0.85 CALCRL (0.39) CALCRLCHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL5018175 0.84 LNPEP (0.40) CALCRLCHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL5019102 0.84 RAB9A (0.46) CALCRLMMP3MMP1MMP2MMP12
SCHEMBL5018201 0.84 HDAC1 (0.44)
SCHEMBL5018124 0.84 HDAC1 (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178490-B2 Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof REMPEX PHARMACEUTICALS, INC. (US) 2012-05-15 US disclosed
US-8178490-B2 Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof REMPEX PHARMACEUTICALS, INC. (US) 2012-05-15 US disclosed
US-20100152098-A1 POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF MPEX PHARMACEUTICALS, INC. (US) 2010-06-17 US disclosed
US-20100152098-A1 POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF MPEX PHARMACEUTICALS, INC. (US) 2010-06-17 US disclosed
WO-2010054102-A2 POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF MPEX PHARMACEUTICALS, INC. (US) 2010-05-14 WO disclosed
US-20080318957-A1 POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF MPEX PHARMACEUTICALS, INC. (US) 2008-12-25 US disclosed
US-20080318957-A1 POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF MPEX PHARMACEUTICALS, INC. (US) 2008-12-25 US disclosed
WO-2008141010-A2 POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF MPEX PHARMACEUTICALS, INC. (US) 2008-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152098-A1 POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF ABCB11, ABCB1, SLC47A1 CALCRL 4740/4885CHRNB2 4860/4885CHRNB4 4858/4885
US-20080318957-A1 POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF ABCB11, ABCB1, SLC47A1 CALCRL 4740/4885CHRNB2 4860/4885CHRNB4 4858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.